PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16891292-0 2006 Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women. Bezafibrate 11-22 junctophilin 3 Homo sapiens 26-30 8060379-6 1994 Bezafibrate did not affect the plasma level of HDL2-TC but reduced the HDL2-TG concentration significantly (P < 0.001). Bezafibrate 0-11 junctophilin 3 Homo sapiens 71-75 11483875-5 2001 After bezafibrate therapy, HDLc increased from 0.79-1.0 mM (p = 0.0008) at the expense of both HDL2 and HDL3 subfractions, apolipoprotein A-I increased from 1.04-1.19 g/l (p = 0.0012), and fibrinogen decreased from 4.45-3.39 g/l (p = 0.0007). Bezafibrate 6-17 junctophilin 3 Homo sapiens 95-99 1397477-5 1992 The marked BZF-induced Tg reduction was associated with a proportional decrease in Apo B, while an increase in total HDL-, HDL2 and HDL3-CHOL, together with a significant increase in Apo AI, was observed. Bezafibrate 11-14 junctophilin 3 Homo sapiens 123-127 7236016-0 1980 Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV. Bezafibrate 10-21 junctophilin 3 Homo sapiens 67-71 7236016-1 1980 The effect of a six-month treatment with bezafibrate on HDL2 and HDL3, measured as cholesterol and apolipoprotein A-I, was studied in 10 hypertriglyceridemic patients. Bezafibrate 41-52 junctophilin 3 Homo sapiens 56-60 3884023-1 1985 In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol. Bezafibrate 14-25 junctophilin 3 Homo sapiens 296-300